Tigen and Memorial Sloan Kettering Cancer Center form development collaboration

Tigen obtains an option for a license to commercially develop a product based on a suite of patent rights and licensed know-how from Memorial Sloan Kettering Cancer Center (MSK) in New York City. Tigen has agreed to support the ongoing Phase 1 clinical trial at MSK for an autologous CD371 CAR T-cell product in relapsed/refractory acute myeloid leukemia (AML) conducted under MSK’s Institutional Review Board (IRB) Protocol #23-016: Phase I trial of CLEc12a (CD371) targeted Armored immune effector cells in patients with Relapsed/refractory Acute Myeloid Leukemia (CLEAR-AML).

Under the terms of the option agreement, collaboration will be intensified around technical and clinical development to accelerate the program to its next stage of clinical development.

Simon R. Eade, Chief Business Officer, Tigen: “With an estimated 20,000 cases of AML in the US each year and a five-year survival rate of roughly 30%, the CLEAR-AML study addresses a significant unmet medical need. The collaboration is focused on bringing a potential AML CAR T therapy with a novel IL-18 armoring to patients with relapsed/refractory AML. We plan to accelerate the development of the asset by combining MSK’s scientific innovation and clinical expertise with Tigen’s manufacturing platform and technical development capabilities. We are proud of this collaboration and have high hopes for the potential it offers to patients with AML across the world.”

Anthony Daniyan, MD, Assistant Attending and Member of the Cellular Therapeutics Center at MSK, says: “This collaboration will accelerate treatments from the bench to the bedside, allowing for today’s technologies in the laboratory to potentially become the therapies of tomorrow.”

This important new collaboration was announced at the MSK Life Sciences Innovation Summit on January 26 during presentations by Dr. Daniyan and Mr. Eade.